A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers

Journal of Nuclear Medicine

Volumn 55, Issue 3, 2014, Pages 515-521

  Carlin, Sean ^a   Zhang, Hanwen ^a   Reese, Megan ^a   Ramos, Nicholas N ^a   Chen, Qing ^a   Ricketts, Sally Ann ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Animal imaging; Autoradiography; Hypoxia; Immunofluorescence; PET

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; CARBONATE DEHYDRATASE IX; DIACETYL BIS(N4 METHYLSEMICARBAZON) F 18; FLORTANIDAZOLE F 18; FLUOROAZOMYCIN ARABINOSIDE F 18; PIMONIDAZOLE; TRACER; UNCLASSIFIED DRUG; COPPER; COPPER (II) DIACETYL DI(N(4) METHYLTHIOSEMICARBAZONE); COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); DIAGNOSTIC AGENT; NITROIMIDAZOLE DERIVATIVE; ORGANOMETALLIC COMPOUND; THIOSEMICARBAZONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; FLUORESCENCE IMMUNOHISTOCHEMISTRY; FROZEN SECTION; HYPOXIA; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; KIDNEY CLEARANCE; MOUSE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TISSUE SPECIFICITY; TUMOR XENOGRAFT; ANIMAL; ANIMAL IMAGING; CELL HYPOXIA; HUMAN; IMMUNOFLUORESCENCE; METABOLISM; METHODOLOGY; PET; TUMOR CELL LINE;

ANIMAL IMAGING; AUTORADIOGRAPHY; HYPOXIA; IMMUNOFLUORESCENCE; PET;

ANIMALS; AUTORADIOGRAPHY; CELL HYPOXIA; CELL LINE, TUMOR; COPPER RADIOISOTOPES; HUMANS; MICE; NITROIMIDAZOLES; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; THIOSEMICARBAZONES;

EID: 84899489980     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.126615     Document Type: Article

References (34)

1. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955;9:539-549.
2. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33:207-214.
3. Russell J, Carlin S, Burke SA, Wen B, Yang KM, Ling CC. Immunohistochemical detection of changes in tumor hypoxia. Int J Radiat Oncol Biol Phys. 2009;73:1177-1186.
4. Le QT, Kong C, Lavori PW, et al. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2007;69:167-175.
5. Swietach P, Hulikova A, Vaughan-Jones RD, Harris AL. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene. 2010;29:6509-6521.
6. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49(suppl 2):129S-148S.
7. Janssen HL, Hoebers FJ, Sprong D, et al. Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors. Radiother Oncol. 2004; 70:91-97.
8. Carlin S, Humm JL. PET of hypoxia: current and future perspectives. J Nucl Med. 2012;53:1171-1174.
9. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155-1160.
10. Grierson JR, Link JM, Mathis CA, Rasey JS, Krohn KA. A radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med. 1989;30:343-350.
11. Maier FC, Kneilling M, Reischl G, et al. Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [18F]- fluoro-azomycinarabino-furanoside ([18F]FAZA). Radiat Oncol. 2011;6:165.
12. Oehler C, O'Donoghue JA, Russell J, et al. 18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. J Nucl Med. 2011;52:437-444.
13. Carlin S, Pugachev A, Sun X, et al. In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression. Nucl Med Biol. 2009;36: 821-831.
14. Carlin S, Khan N, Ku T, Longo VA, Larson SM, Smith-Jones PM. Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts. PLoS ONE. 2010;5:e10857.
15. Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med. 2008;49:1177-1182.
16. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA,Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4- methylthiosemicarbazone). J Nucl Med. 2008;49:201-205.
17. Chen L, Zhang Z, Kolb HC, Walsh JC, Zhang J, Guan Y. 18F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with 18F-FMISO. Nucl Med Commun. 2012;33:1096-1102.
18. Mortensen LS, Johansen J, Kallehauge J, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012; 105:14-20.
19. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
20. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol. 2011;101:369-375.
21. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40:177-183.
22. McCall KC, Humm JL, Bartlett R, Reese M, Carlin S. Copper-64-diacetyl- bis(N (4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia. Int J Radiat Oncol Biol Phys. 2012;84:e393-e399.
23. Kaluz S, Kaluzová M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta. 2009;1795:162-172.
24. Shin KH, Diaz-Gonzalez JA, Russell J, Chen Q, Burgman P, Li XF, Ling CC. Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole. Cancer Biol Ther. 2007;6:70-75.
25. Taghian A, Lespinasse F, Guichard ME. Radiosensitization by the combination of etanidazole (SR-2508) and pimonidazole (Ro 03-8799) in human tumor xenografts. Int J Radiat Oncol Biol Phys. 1991;21:1535-1540.
26. Isoda T, Engles J, Wahl R. Time dependence of hypoxia-specific accumulation of pimonidazole in rodent breast cancers [abstract]. J Nucl Med. 2010;51(suppl 2):228.
27. O'Donoghue JA, Zanzonico P, Pugachev A, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4- methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493-1502.
28. Hansen AE, Kristensen AT, Jørgensen JT, et al. 64Cu-ATSM and 18FDG PET uptake and 64Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry. Radiat Oncol. 2012; 7:89.
29. Bowen SR, van der Kogel AJ, Nordsmark M, Bentzen SM, Jeraj R. Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. Nucl Med Biol. 2011;38:771- 780.
30. Hammond EM, Giaccia AJ. The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun. 2005;331:718-725.
31. Nordsmark M, Eriksen JG, Gebski V, Alsner J, Horsman MR, Overgaard J. Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol. 2007;83:389-397.
32. Kleiter MM, Thrall DE, Malarkey DE, Ji X, Lee DY, Chou SC, Raleigh JA. A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker. Int J Radiat Oncol Biol Phys. 2006;64:592-602.
33. Zhang X, Lin Y, Gillies RJ. Tumor pH and its measurement. J Nucl Med. 2010;51:1167-1170.
34. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, Koutcher JA. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551-560.